問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2012-07-01 - 2019-08-31
Condition/Disease
A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis
Test Drug
Isoniazid tablet formulated with excipient HUEXC030
Participate Sites13Sites
Terminated13Sites
2014-04-01 - 2016-09-30
Squamous Cell Carcinoma of the Head and Neck
Javlor
Participate Sites7Sites
Terminated7Sites
2013-10-01 - 2020-07-31
Locally Advanced or Metastatic Pancreatic Cancer
NC-6004
Participate Sites17Sites
Terminated17Sites
Division of Hematology & Oncology
2012-11-01 - 2014-12-31
advanced breast cancer
JAVLOR
Participate Sites4Sites
Terminated3Sites
Study ended1Sites
2021-09-01 - 2022-11-30
Participate Sites12Sites
Recruiting10Sites
Terminated2Sites
2007-08-30 - 2009-07-30
Participate Sites2Sites
2013-04-16 - 2016-08-18
ANKYLOSING SPONDYLITIS
Tofacitinib (CP-690550)
Participate Sites3Sites
Division of General Internal Medicine
2014-07-31 - 2017-03-30
Severely Active Rheumatoid Arthritis
Tofacitinib (Xeljanz)
Participate Sites6Sites
Terminated6Sites
2014-07-15 - 2021-03-30
NA
ARN-509; softgel capsule
Participate Sites5Sites
Recruiting5Sites
2011-03-01 - 2016-06-30
Unresectable Hepatocellular Carcinoma
TSU-68
Participate Sites14Sites
Terminated14Sites
全部